Anika Therapeutics P/E 2024

Anika Therapeutics Aktienanalyse

What does Anika Therapeutics do?

Anika Therapeutics Inc is a global biotechnology company specializing in the development and manufacturing of therapeutic products for orthopedic, ophthalmologic, and dermatologic treatment. It was founded in 1992 in Bedford, Massachusetts and has since maintained its headquarters there while expanding its operations worldwide. Business model Anika Therapeutics' business model is based on the development, manufacturing, and commercialization of innovative and cost-effective medical devices that use natural substances to enable rapid and powerful repair of the human body in various orthopedic, ophthalmologic, and dermatologic conditions. The company leverages its expertise in hyaluronan biology and technology to produce products based on this substance for the regeneration and healing of tissues such as cartilage, skin, and eyes. History Anika Therapeutics was founded by Charles Sherwood and Jeffrey Palmer to develop a synthetic hyaluronic acid product for the treatment of joint disorders. The first clinical study was conducted in 1996, and Anika received FDA approval for the product, marketed as Orthovisc, in 1999. Since then, Anika has expanded its presence in the industry through acquisitions, partnerships, and expansion into new geographical areas. Divisions Orthopedics In orthopedics, Anika Therapeutics offers a wide range of products for the treatment of joint disorders such as osteoarthritis and arthritis. These include Orthovisc, the company's original product, as well as Monovisc, a single-component viscosupplement that allows for easy injection into the joint, thus reducing the procedure and recovery time. Another product is Cingal, a combination product of hyaluronic acid and corticosteroid that provides effective pain relief. Ophthalmology Anika Therapeutics also manufactures products for ophthalmology. The company has a portfolio of products used for surgical procedures such as cataract surgery and vitrectomy (a surgery on the eye's vitreous body). These are available under the brand names Visian and Amvisc. Dermatology Anika Therapeutics is also active in dermatology, where it offers products for skin regeneration. This portfolio includes solutions such as Hyalofill, a hyaluronic acid-based filler substance used for restoring skin elasticity and treating wrinkles and scars. In summary, Anika Therapeutics is a global biotechnology company specializing in the development, manufacturing, and commercialization of therapeutic products in the field of orthopedics, ophthalmology, and dermatology. The company leverages its expertise in hyaluronan biology and technology to develop innovative and cost-effective medical devices that enable rapid and powerful repair of the human body in various conditions. Since its founding in 1992, the company has built a successful history of growth and expansion through acquisitions, partnerships, and expansion into new geographical areas. Anika Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Anika Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Anika Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Anika Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Anika Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Anika Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Anika Therapeutics stock

What is the price-to-earnings ratio of Anika Therapeutics?

The price-earnings ratio of Anika Therapeutics is currently -123.34.

How has the price-earnings ratio of Anika Therapeutics changed compared to last year?

The price-to-earnings ratio of Anika Therapeutics has increased by 2,502.11% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Anika Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Anika Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Anika Therapeutics affect the company?

An increase in the price-earnings ratio of Anika Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Anika Therapeutics affect the company?

A decrease in the price-earnings ratio of Anika Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Anika Therapeutics?

Some factors that influence the price-earnings ratio of Anika Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Anika Therapeutics pay?

Over the past 12 months, Anika Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Anika Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Anika Therapeutics?

The current dividend yield of Anika Therapeutics is .

When does Anika Therapeutics pay dividends?

Anika Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Anika Therapeutics?

Anika Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Anika Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Anika Therapeutics located?

Anika Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Anika Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Anika Therapeutics from 9/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did Anika Therapeutics pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of Anika Therapeutics in the year 2023?

In the year 2023, Anika Therapeutics distributed 0 USD as dividends.

In which currency does Anika Therapeutics pay out the dividend?

The dividends of Anika Therapeutics are distributed in USD.